Why Now?
Spurred by George Schett and Andreas Mackensen’s remarkable CAR-T results in SLE, the immunotherapy revolution for autoimmune diseases is the next “million-dollar question”.
Shifting from broad symptomatic treatment to wiping out the wrongdoings for sustained disease modification, cell therapies, cell engagers, and cell-depleting antibodies are promising a whole new level of therapeutic efficacy.
Beacon Targeted Therapies Trial Database cites 62 clinical trials in immune-mediated diseases with cell therapy alone, of which 42 are recruiting patients in 2024.
Combined with immune tolerization to rebuild a less aberrant immune system through engineered Tregs and antigen-specific immune tolerance strategies; immune reset and subsequent reconstitution is gathering industry momentum, to change treatment paradigms dramatically.
But despite this industry “gold rush” the average biotech-pharma collaboration takes 8 months, elongated from not finding the right individuals sooner.
The Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind, laying enabled partnering on top of hyper-relevant scientific discussion specifically for immune reset and reconstitution therapies.
Pharma will develop scientific growth strategies and evaluate modalities side-by-side, and biotech accesses the right gatekeepers for decision makers, or decision-makers themselves specific to immunology deal-making.
![CAR-TCR-348-min (1) CAR-TCR-348-min (1)](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/CAR-TCR-348-min-1-scaled.jpg)
![CAR-TCR-439-min CAR-TCR-439-min](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/CAR-TCR-439-min-scaled.jpg)
SPEAKERS
![Chris Gagliardi Chris Gagliardi](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/Chris-Gagliardi.jpg)
Chris Gagliardi
Principal
Sanofi Ventures
![Nicola La Monica Nicola La Monica](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/Nicola-La-Monica.jpg)
Nicola La Monica
Senior Director, Strategic Search & Evaluation
Johnson & Johnson
![Swarna Balasubramanian Swarna Balasubramanian](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/Swarna-Balasubramanian.jpg)
Swarna Balasubramanian
Associate Director, Search & Evaluation Respiratory & Immunology
AstraZeneca
![Melissa Matzelle Melissa Matzelle](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/Melissa-Matzelle.jpg)
Melissa Matzelle
Director, Immunology Search & Evaluation
AbbVie
![Emma Smith Emma Smith](https://autoimmunity-partnering.com/wp-content/uploads/sites/975/2024/07/Emma-Smith.jpg)
Emma Smith
Head of Immune Reset
UCB